Investigational drug · Phase 3
Esflurbiprofen System
Also called: EFTS
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Contusions, Ankle Sprains.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
5
Any phase or sponsor naming "Esflurbiprofen System"
First trial start
2025
Feb 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Esflurbiprofen System", any sponsor or status.
Conditions studied
As listed on its trial records.
- Contusions
- Ankle Sprains
Largest trials
Live from ClinicalTrials.gov: studies naming "Esflurbiprofen System" as an intervention, largest first.
- Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With ContusionsPivotal-lookingCompleted
Teikoku Seiyaku Co., Ltd.Industry
NCT06871046 · 221 participants · Start Feb 20, 2025 · Primary completion Sep 22, 2025
Drug: Esflurbiprofen Topical System (EFTS) · For: Contusions
Sites: Siemensstr, Germany; Sportschule Puch, Germany; Römerstraße, Germany · 5 sites in all
Teikoku Seiyaku Co., Ltd.Industry
NCT07307794 · 90 participants · Start Jan 19, 2026 · Primary completion Mar 3, 2026
Drug: Esflurbiprofen Topical System · For: Healthy Participants
Sites: Am Sportpark Muengersdorf 6, Germany
- Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.Pivotal-lookingCompleted
Teikoku Seiyaku Co., Ltd.Industry
NCT06866613 · 70 participants · Start Mar 31, 2025 · Primary completion Oct 18, 2025
Drug: Esflurbiprofen Topical System (EFTS); Placebo Patch · For: Ankle Sprains
Sites: Siemensstr, Germany; Sportschule Puch, Germany; Römerstraße, Germany · 5 sites in all
Teikoku Seiyaku Co., Ltd.Industry
NCT06870422 · 28 participants · Start Feb 28, 2025 · Primary completion Apr 3, 2025
Drug: Esflurbiprofen Topical System · For: Healthy
Sites: Mainzerhofplatz, Germany
Teikoku Seiyaku Co., Ltd.Industry
NCT06823284 · 26 participants · Start Jan 21, 2025 · Primary completion Feb 12, 2025
Drug: Esflurbiprofen Topical System; Flurbiprofen tablet · For: Healthy
Sites: Mainzerhofplatz 14, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Dose recovery after repeated drug administration via nasogastric feeding tubes under clinically relevant conditions: a novel in vitro model.
Urbaniak J, Hobritz E, Höhn JG, et al. · Int J Pharm 2026
- Development and implementation of the MED4TUBE evidence-based care bundle to reduce medication errors in enteral feeding tubes: A quality improvement study.
Memili S, Sezer RE, Akçay K, et al. · Am J Clin Nutr 2026
- Access to an mHealth Tool for Symptom Management in Pediatric Oncology Care: Triangulation Study.
Höök A, Forsgren E, Björk M, et al. · JMIR Form Res 2026
- The Electronic Faces Thermometer Scale (eFTS)-Construct Validity for Pain Assessment in Pediatric Postoperative Care in Sweden.
Höök A, Hylén M, Nilsson S, et al. · Paediatr Anaesth 2026
- Formulation and optimization of gastroretentive tablets containing famotidine in combination with antacids: In vitro evaluations and stability studies.
Aldosari AM, Mahrous GM, Radwan AA, et al. · Saudi Pharm J 2026
- The Effects of Emotional Freedom Technique on Pelvic Pain and Quality of Life in Women Diagnosed with Endometriosis: A Randomized Controlled Trial.
Çuvadar A, Guksu Z, Ateş S · J Integr Complement Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.